J
Jms Bartlett
Researcher at Ontario Institute for Cancer Research
Publications - 25
Citations - 907
Jms Bartlett is an academic researcher from Ontario Institute for Cancer Research. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 7, co-authored 23 publications receiving 750 citations. Previous affiliations of Jms Bartlett include Nottingham University Hospitals NHS Trust & Edinburgh Cancer Research Centre.
Papers
More filters
Journal ArticleDOI
Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
Ali Hr,Elena Provenzano,S-J Dawson,Fiona M. Blows,Bin Liu,Mitulkumar Shah,Helena M. Earl,Christopher J. Poole,Louise Hiller,Janet A. Dunn,Sarah Bowden,Chris Twelves,Jms Bartlett,Jms Bartlett,Sma Mahmoud,Emad A. Rakha,Ian O. Ellis,S Liu,Dongxia Gao,Torsten O. Nielsen,Paul D.P. Pharoah,Carlos Caldas +21 more
TL;DR: The presence of CD8+ T cells in breast cancer is associated with a significant reduction in the relative risk of death from disease in both the ER-negative and ER-positive HER2-positive subtypes and may improve risk stratification in Breast cancer patients classified into these subtypes.
Journal ArticleDOI
Recommendations for HER2 testing in the UK
Ian O. Ellis,Mitchell Dowsett,Jms Bartlett,Rosemary A. Walker,Timothy G. Cooke,William J. Gullick,Barry A. Gusterson,Elizabeth Mallon,P. Barrett Lee +8 more
TL;DR: Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin®), which has recently been licensed for the treatment of metastatic disease.
Journal ArticleDOI
Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial
Jms Bartlett,Peter Canney,A. M. Campbell,David Cameron,Jenny L Donovan,Janet A. Dunn,Helena M. Earl,Adele Francis,Peter Hall,V. Harmer,Helen B Higgins,L. Hillier,Claire Hulme,Luke Hughes-Davies,Andreas Makris,Adrienne Morgan,Christopher McCabe,Sarah E Pinder,Christopher J. Poole,Daniel Rea,Nigel Stallard,Robert Stein +21 more
TL;DR: The OPTIMA trial, which has just opened to recruitment in the UK, is the latest addition to trials in this area, and is the first to focus on the relative cost-effectiveness of alternate predictive assays.
Journal ArticleDOI
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial
Ali Hr,Aliakbar Dariush,Jeremy Thomas,Elena Provenzano,Elena Provenzano,Janet A. Dunn,Louise Hiller,A-L Vallier,Jean Abraham,T Piper,Jms Bartlett,Jms Bartlett,David Cameron,Larry Hayward,James D. Brenton,Paul D.P. Pharoah,Mike Irwin,Nicholas A. Walton,Helena M. Earl,Carlos Caldas +19 more
TL;DR: Lymphocyte density in pre-treatment biopsies was validated as an independent predictor of pCR in breast cancer and Computational pathology is emerging as a viable and objective means of identifying predictive biomarkers for cancer patients.
Journal ArticleDOI
The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy : a Dutch TEAM study analysis
C.C. Engels,A. Charehbili,C.J.H. van de Velde,Esther Bastiaannet,A. Sajet,Hein Putter,E. A. van Vliet,R. L. P. Van Vlierberghe,Vincent T.H.B.M. Smit,Jms Bartlett,Caroline Seynaeve,G.J. Liefers,Peter J. K. Kuppen +12 more
TL;DR: Tregs and the tumor IS presented in this study harbor prognostic value for sequentially endocrine-treated HR+ve postmenopausal BC patients, but not for solely exemestane-treated patients, and could be used as a clinical risk stratification tool to guide adjuvant treatment in this BC population.